Astellas- Drug ASP546C for CLDN18.2-expressing solid tumors (546C-CL-0201)

Study Details

Full Title

[546C-CL-0201] A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants with CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types

Principal Investigator

John

Strickler

Protocol Number

PRO00119707

NCT ID

NCT07488676

Phase

I/II

Enrollment Status

Open to Enrollment

ClinicalTrials.gov